Harrington KJ, Cohen EEW, Soulieres D, Dinis J, et al. Pembrolizumab versus methotrexate, docetaxel, or cetuximab in recurrent or metastatic head and neck squamous cell carcinoma (KEYNOTE-040): Subgroup analysis by pattern of disease recurrence. Oral Oncol 2023;147:106587.
PMID: 37925894